CIPLA.NSECipla Ltd.

Indian equity markets opened weak on Friday amid persistent geopolitical tensions and the ongoing Q4 earnings season. Sensex fell 400 points to 77,263, while Nifty declined 100 points in early trade. IT, financial, and pharma stocks faced heavy selling pressure, with Cipla, Infosys, Dr Reddy’s, Sun Pharma, TCS, and ICICI Bank as top laggards. FMCG and chemical stocks provided some support.

… Delhi: Drugmakers Cipla and Sun Pharmaceuticals are undertaking, voluntary recalls of … facility in India. Meanwhile, Sun Pharma is recalling three batches of … . The drug was manufactured by Taro Pharmaceuticals (a wholly owned subsidiary of Sun …

… Delhi: Drugmakers Cipla and Sun Pharmaceuticals are undertaking, voluntary recalls of … facility in India. Meanwhile, Sun Pharma is recalling three batches of … . The drug was manufactured by Taro Pharmaceuticals (a wholly owned subsidiary of Sun …

Financials and automakers dragged Indian shares down on Thursday, as Brent crude topped $100 a barrel after Iran seized two ships in the Strait of Hormuz and peace talks showed no sign of resuming. The Nifty 50 lost 0.84% to 24,173.05, while the BSE Sensex shed 1.09% to 77,664. Brent crude rose for a fourth straight session to trade above $103 a barrel as uncertainty over Middle East peace talks lingered. Other Asian markets fell 0.4%. HSBC downgraded Indian equities to “underweight” from “neutral” on Thursday, citing the impact of high energy prices on India. Foreign investors sold a net $4.4 billion worth of Indian shares in April and $18.6 billion so far in 2026. “Despite lingering Mideast tensions, April’s rebound after March’s slump suggests domestic investors are taking comfort in valuations and betting on an early resolution, even as foreign investors stay wary of high oil prices and rupee weakness,” said G. Chokkalingam, founder and head of research at Equinomics Research. Including the session’s losses, the Nifty and Sensex are up about 8% each in April, partially recovering from the more than 11% drop in March.

Financials and automakers dragged Indian shares down on Thursday, as Brent crude topped $100 a barrel after Iran seized two ships in the Strait of Hormuz and peace talks showed no sign of resuming. The Nifty 50 lost 0.84% to 24,173.05, while the BSE Sensex shed 1.09% to 77,664. Brent crude rose for a fourth straight session to trade above $103 a barrel as uncertainty over Middle East peace talks lingered. Other Asian markets fell 0.4%. HSBC downgraded Indian equities to “underweight” from “neutral” on Thursday, citing the impact of high energy prices on India. Foreign investors sold a net $4.4 billion worth of Indian shares in April and $18.6 billion so far in 2026. “Despite lingering Mideast tensions, April’s rebound after March’s slump suggests domestic investors are taking comfort in valuations and betting on an early resolution, even as foreign investors stay wary of high oil prices and rupee weakness,” said G. Chokkalingam, founder and head of research at Equinomics Research. Including the session’s losses, the Nifty and Sensex are up about 8% each in April, partially recovering from the more than 11% drop in March.

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to depart in the coming months. Gupta joined Alkem from Cipla and has a strong background in the Indian pharmaceutical market.

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to depart in the coming months. Gupta joined Alkem from Cipla and has a strong background in the Indian pharmaceutical market.

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.